Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

(2021) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

(2020) Hope S Rugo et al.   Future Oncology

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

(2020) K. Kalinsky et al.   ANNALS OF ONCOLOGY

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/Akt signaling pathway

(2019) Genxiong Tang et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K/AKT signaling

(2018) Qing‑Zhi Gu et al.   Molecular Medicine Reports

Trop2 is a potential biomarker for the promotion of EMT in human breast cancer

(2018) Wei Zhao et al.   ONCOLOGY REPORTS

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT

(2017) Xinxing Li et al.   Oncotarget

Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors

(2016) Emanuela Guerra et al.   CLINICAL CANCER RESEARCH

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

(2016) Bernard Pereira et al.   Nature Communications

Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma

(2015) Kanlayanee Sawanyawisuth et al.   Annals of Hepatology

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

(2015) Giovanni Ciriello et al.   CELL

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Trop-2 Is a Determinant of Breast Cancer Survival

(2014) Federico Ambrogi et al.   PLoS One

A novel human Fab antibody for Trop2 inhibits breast cancer growthin vitroandin vivo

(2013) Hong Lin et al.   INTERNATIONAL JOURNAL OF CANCER

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

(2012) Laura J. Esserman et al.   JOURNAL OF CLINICAL ONCOLOGY

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT